OCT 09, 2019 3:42 PM PDT

Cannabidiol's Role in Psychiatry

WRITTEN BY: Kara Marker

How can health professionals in the clinical psychiatry field make sense of cannabis products boasting various health claims? One professor’s presentation at the 2019 Psych Congress sought to address this issue, providing clinicians insight on how to advise their patients interested in cannabis products to supplement their health.

The 2019 Psych Congress was held in San Diego, California last week and consisted of psychiatrists, physician assistants, nurse practitioners, psychologists, and any other healthcare professional in the mental health field. As many clinicians and researchers do at the beginning of a discussion on cannabidiol (CBD) or other non-psychoactive components of cannabis, University of California, San Francisco (UC-SF) professor Andrew Penn, RN, MS, NP, PMHNP-BC, began his presentation by explaining the differences between the two arguably most infamous cannabinoids: tetrahydrocannabinol (THC) and CBD.

While making it clear that THC is psychoactive and CBD is not, Penn acknowledged that it is still not a case of “good guy” and “bad guy.” The reality is that the scientific literature lacks a sufficient amount of reliable clinical trials to back up most health claims for CBD and other cannabis-based compounds. In his presentation, Penn reviewed existing studies supporting CBD use in various disease states such as anxiety, depression, post-traumatic stress disorder (PTSD), schizophrenia, sleep disorders, autism, and eating disorders. Some small clinical trials have been done to provide evidence for therapeutic uses of CBD in this disease states, but most of the evidence is anecdotal.

Penn explained that THC reduces activity at both the “default mode” and the “salience networks” of the brain, a multifaceted influence that is largely responsible for the “high” associated with cannabis products. CBD limits THC’s psychoactive influence, so the ratio of CBD to THC in various cannabis products has a large impact over the product’s effect on the person utilizing it.

Penn recommends that for patients interested in CBD, clinicians should advise oral formulations over inhaled products because of recent negative health implications association with inhalation. His maximum recommended dose of CBD as 0.25 mg/kg; his instructions are to start low and increase slowly.

“The way I see CBD in psychiatric practice right now is that we are really in an in-between space where we have a small handful of studies, usually looking at very large doses of CBD in disease states like schizophrenia and anxiety, and we do not have good clinical data on smaller doses, which are more representative of what patients are generally taking and what they can access through dispensaries,” Penn said in a Psychiatry Advisor article. “It creates this disconnect between what we are seeing in our offices and what the small amount of research has shown us. Until we get more data, we have to work with our patients and find out what they are doing, and, ideally, report that into a larger space and publish it so that other clinicians can learn from it.”

Sources: Psychiatry Advisor, Psychiatry & Behavioral Health Learning Network

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JUL 29, 2020
Cannabis Sciences
Stimulants, Cannabis, and Medical Cannabis Laws
JUL 29, 2020
Stimulants, Cannabis, and Medical Cannabis Laws
Lesbian, gay, and bisexual populations may be at a higher risk of prescription stimulant use, based on a new examination ...
AUG 05, 2020
Cannabis Sciences
Cannabis Might Trigger Heart Problems Says AHA
AUG 05, 2020
Cannabis Might Trigger Heart Problems Says AHA
The American Heart Association (AHA) has produced a new statement about medical marijuana and recreational cannabis. The ...
SEP 10, 2020
Cannabis Sciences
Legalizing Cannabis Does Not Lead to Teenage Substance Abuse
SEP 10, 2020
Legalizing Cannabis Does Not Lead to Teenage Substance Abuse
Some say that decriminalizing cannabis may lead to an uptick in young people abusing the substance. Countering this fear ...
SEP 13, 2020
Cannabis Sciences
Public Perceive Legal Cannabis as Too Pricy
SEP 13, 2020
Public Perceive Legal Cannabis as Too Pricy
Researchers have found that over a third of people think legal cannabis is safer and of higher quality than that availab ...
NOV 13, 2020
Health & Medicine
Cannabis Oil May Help Burning Mouth Syndrome
NOV 13, 2020
Cannabis Oil May Help Burning Mouth Syndrome
If you’ve ever scalded the top of your mouth with very hot food or drink you'll know the pain it can cause. No ...
NOV 23, 2020
Health & Medicine
Federal Report Shows Teen Marijuana Treatment Admissions Have Been Falling
NOV 23, 2020
Federal Report Shows Teen Marijuana Treatment Admissions Have Been Falling
Concerns that the legalization of recreational marijuana might cause an upswing in young people misusing the drug have b ...
Loading Comments...